
Oncopeptides Q4 - Germany Drives Sales

Revenues in Q4 came in at SEK10m, slightly softer than we had estimated, albeit still showing growth, mainly in Germany. The number of prescribers increased, boding well for H1 2025. Oncopeptides is also making progress in licensing discussions and its preclinical programmes. We make moderate revisions to our financial projections and fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Oncopeptides Q4 - Germany Drives Sales